Clinical trial • Phase III • Oncology
Clinical trial in Hormone receptor positive early breast cancer
Phase III trial for Hormone receptor positive early breast cancer. 63 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Hormone receptor positive early breast cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 12-12-2025
- First CTIS Authorization Date
- 31-03-2026
Trial design
Phase III trial across 15 sites in Spain.
- Target Sample Size
- 63
Recruitment
- Planned Sample Size
- 63
- Recruitment Window Months
- 28
Geography
- Total Number Of Sites
- 15
- Total Number Of Participants
- 63
Spain
- Earliest CTIS Part Ii Submission Date
- 25-03-2026
- Latest Decision Or Authorization Date
- 31-03-2026
- Processing Time Days
- 6
- Number Of Sites
- 15
- Number Of Participants
- 57
Sites
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Oncology
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitario De Leon
- Department Name
- Oncology
- Contact Person Name
- Ana Lopez Gonzalez
- Contact Person Email
- alopezgo@saludcastillayleon.es
- Site Name
- Hospital Universitari General De Catalunya
- Department Name
- Oncology
- Contact Person Name
- Vanesa Ortega Cebrian
- Contact Person Email
- vortega@oncorosell.com
- Site Name
- Hospital Universitario De Jaen
- Department Name
- Oncology
- Contact Person Name
- Alicia Cano Jimenez
- Contact Person Email
- aliciacanojimenez@gmail.com
- Site Name
- University Clinical Hospital Virgen De La Arrixaca
- Department Name
- Oncology
- Contact Person Name
- Jose Luis Alonso Romero
- Contact Person Email
- josel.alonso2@carm.es
- Site Name
- Hospital Universitario Fundacion Alcorcon
- Department Name
- Oncology
- Contact Person Name
- Diana Moreno Munoz
- Contact Person Email
- dmmunoz@salud.madrid.org
- Site Name
- Institut Catala D'oncologia
- Department Name
- Oncology
- Contact Person Name
- Sonia Del Barco
- Contact Person Email
- sdelbarco@iconcologia.net
- Site Name
- Salut Sant Joan De Reus
- Department Name
- Oncology
- Contact Person Name
- Alba Cochs Sarobe
- Contact Person Email
- alba.cochs@salutsantjoan.cat
- Site Name
- Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada
- Department Name
- Oncology
- Contact Person Name
- Clara Martinez Vila
- Contact Person Email
- cmartinezv@althaia.cat
- Site Name
- Complexo Hospitalario Universitario De Santiago
- Department Name
- Oncology
- Contact Person Name
- Rafael Lopez Lopez
- Contact Person Email
- rafael.lopez.lopez@sergas.es
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Oncology
- Contact Person Name
- Fabricio Racca
- Contact Person Email
- fracca@nextoncology.eu
- Site Name
- Hospital Universitario Virgen De Las Nieves
- Department Name
- Oncology
- Contact Person Name
- Cristina Alba Torres
- Contact Person Email
- cr.albatorres@gmail.com
- Site Name
- Parc Tauli Hospital Universitari
- Department Name
- Oncology
- Contact Person Name
- Elsa Dalmau Portulas
- Contact Person Email
- edalmau@tauli.cat
- Site Name
- Hospital Quironsalud Malaga
- Department Name
- Oncology
- Contact Person Name
- Manuel Angel Cobo Dols
- Contact Person Email
- manuelcobodols@yahoo.es
- Site Name
- Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida
- Department Name
- Oncology
- Contact Person Name
- Serafin Morales Murillo
- Contact Person Email
- serafinmorales01@gmail.com
Sponsor
Primary sponsor
- Full Name
- Laboratorios Farmaceuticos Rovi S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)